Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 15/20 | 0.61 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 3/20 | 0.45 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CTSV | O60911 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4043159 | 0.99 | CTSK (0.61) | CTSKSMYD3CTSSCCR1CTSV | |
| SCHEMBL4041748 | 0.96 | CTSK (0.66) | CTSKCTSSCTSL | |
| SCHEMBL4039951 | 0.96 | CTSK (0.57) | CTSKSMYD3CTSSCCR1CTSV | |
| SCHEMBL4041640 | 0.96 | CTSK (0.57) | CTSKSMYD3CTSSCCR1CTSV | |
| SCHEMBL4040365 | 0.95 | CTSK (0.57) | CTSKSMYD3CTSSCCR1CTSV | |
| SCHEMBL4041902 | 0.95 | CTSK (0.57) | CTSKSMYD3CTSSCCR1CTSV | |
| SCHEMBL4038609 | 0.95 | CTSK (0.65) | CTSKCTSSCTSL | |
| SCHEMBL4039030 | 0.95 | CTSK (0.58) | CTSKSMYD3CTSSCCR1CTSV | |
| SCHEMBL4042177 | 0.95 | CTSK (0.58) | CTSKSMYD3CTSSCCR1CTSV | |
| SCHEMBL4046217 | 0.95 | CTSK (0.64) | CTSKSMYD3CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| EP-1463728-B1 | FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2009-01-14 | — | — | EP | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | claimed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | claimed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | CTSK 2/4885SMYD3 4011/4885CTSS 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.